J
Joost P. Schanstra
Researcher at French Institute of Health and Medical Research
Publications - 95
Citations - 4769
Joost P. Schanstra is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Receptor & Kidney disease. The author has an hindex of 31, co-authored 81 publications receiving 4301 citations. Previous affiliations of Joost P. Schanstra include Paul Sabatier University & Mahidol University.
Papers
More filters
Journal ArticleDOI
Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
David M. Good,Petra Zürbig,Àngel Argilés,Hartwig W. Bauer,Georg M. N. Behrens,Joshua J. Coon,Mohammed Dakna,Stéphane Decramer,Christian Delles,Anna F. Dominiczak,Jochen H. H. Ehrich,Frank Eitner,Danilo Fliser,Moritz Frommberger,Arnold Ganser,Mark Girolami,Igor Golovko,Wilfried Gwinner,Marion Haubitz,Stefan Herget-Rosenthal,Joachim Jankowski,Holger Jahn,George Jerums,Bruce A. Julian,Markus Kellmann,Volker Kliem,Walter Kolch,Andrzej S. Krolewski,Andrzej S. Krolewski,Mario Luppi,Ziad A. Massy,Michael Melter,Christian Neusüss,Jan Novak,Karlheinz Peter,Kasper Rossing,Harald D. Rupprecht,Joost P. Schanstra,Eric Schiffer,Jens-Uwe Stolzenburg,Lise Tarnow,Dan Theodorescu,Visith Thongboonkerd,Raymond Vanholder,Eva M. Weissinger,Harald Mischak,Philippe Schmitt-Kopplin +46 more
TL;DR: The establishment of a reproducible, high resolution method for peptidome analysis of naturally occurring human urinary peptides and proteins, ranging from 800 to 17,000 Da, using samples from 3,600 individuals analyzed by capillary electrophoresis coupled to MS is reported.
Journal ArticleDOI
Clinical proteomics: A need to define the field and to begin to set adequate standards.
Harald Mischak,Rolf Apweiler,Rosamonde E. Banks,Mark R. Conaway,Joshua J. Coon,Anna F. Dominiczak,Jochen H. H. Ehrich,Danilo Fliser,Mark Girolami,Henning Hermjakob,Denis F. Hochstrasser,Denis F. Hochstrasser,Joachim Jankowski,Bruce A. Julian,Walter Kolch,Ziad A. Massy,Christian Neusuess,Jan Novak,Karlheinz Peter,Kasper Rossing,Joost P. Schanstra,O. John Semmes,Dan Theodorescu,Visith Thongboonkerd,Eva M. Weissinger,Jennifer E. Van Eyk,Tadashi Yamamoto +26 more
TL;DR: It is argued that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples, but should be to address clinically relevant questions and to improve the state-of-the‐art, both in diagnosis and in therapy of diseases.
Journal ArticleDOI
Recommendations for Biomarker Identification and Qualification in Clinical Proteomics
Harald Mischak,Guenter Allmaier,Rolf Apweiler,Teresa K. Attwood,Marc Baumann,Ariela Benigni,Samuel E. Bennett,Rainer Bischoff,Erik Bongcam-Rudloff,Giovambattista Capasso,Joshua J. Coon,Patrick C. D'Haese,Anna F. Dominiczak,Mohammed Dakna,Hassan Dihazi,Jochen H. H. Ehrich,Patricia Fernández-Llama,Danilo Fliser,Jørgen Frøkiær,Jérôme Garin,Mark Girolami,William S. Hancock,Marion Haubitz,Denis F. Hochstrasser,Rury R. Holman,John P. A. Ioannidis,Joachim Jankowski,Bruce A. Julian,Jon B. Klein,Walter Kolch,Theo M. Luider,Ziad A. Massy,William B. Mattes,Franck Molina,Bernard Monsarrat,Jan Novak,Karlheinz Peter,Peter Rossing,Marta Sanchez-Carbayo,Joost P. Schanstra,O. John Semmes,Goce Spasovski,Dan Theodorescu,Visith Thongboonkerd,Raymond Vanholder,Timothy D. Veenstra,Eva M. Weissinger,Tadashi Yamamoto,Antonia Vlahou +48 more
TL;DR: It is asserted that successful studies generally use suitable statistical approaches for biomarker definition and confirm results in independent test sets and a brief set of practical and feasible recommendations are described for investigators to properly identify and qualify proteomic biomarkers, which could also be used as reporting requirements.
Journal ArticleDOI
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future.
David M. Good,Visith Thongboonkerd,Jan Novak,Jean-Loup Bascands,Joost P. Schanstra,Joshua J. Coon,Anna Dominiczak,Harald Mischak +7 more
TL;DR: The view on proteomics for biomarker discovery is expressed by addressing multiple relevant issues, including the inherent differences between biological fluids and how these differences affect current analytical approaches and experimental design to maximize the efficiency of moving from the bench to the bedside.
Journal ArticleDOI
LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis
Jean-Philippe Pradere,Julie Klein,Sandra Grès,Charlotte Guigné,Eric Neau,Philippe Valet,Denis Calise,Jerold Chun,Jean-Loup Bascands,Jean-Sébastien Saulnier-Blache,Joost P. Schanstra +10 more
TL;DR: LPA, likely acting through LPA1, is involved in obstruction-induced TIF, and the LPA2 or LPA4 receptor might be a pharmaceutical target to treat renal fibrosis.